Lukas Bernhard Krone

Lukas Bernhard Krone

Auto-generated profile, based on publicly available information

Lukas Bernhard Krone

Department of Physiology, Anatomy and Genetics, University of Oxford

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Journal of Sleep Research
Verified
Journal Article
Open access
DRDieter Riemanm
Dieter Riemanm
CEColin A. Espie
Colin A. Espie
EAEllemarije Altena
Ellemarije Altena
Erna Sif ArnardóttirErna Sif Arnardóttir
Erna Sif Arnardóttir
CBChiara Baglioni
Chiara Baglioni
KSKai Spiegelhalder
Kai Spiegelhalder
Summary: Progress in the field of insomnia since 2017 necessitated this update of the European Insomnia Guideline. Recommendations for the diagnostic procedure for insomnia and its comorbidities are: clinical interview (encompassing sleep and medical history); the use of sleep questionnaires and diaries (and physical examination and additional measures where indicated) (A). Actigraphy is not recommended for the routine evaluation of insomnia (C), but may be useful for differential‐diagnostic purposes (A). Polysomnography should be used to evaluate other sleep disorders if suspected (i.e. periodic limb movement disorder, sleep‐related breathing disorders, etc.), treatment‐resistant insomnia (A) and for other indications (B). Cognitive‐behavioural therapy for insomnia is recommended as the first‐line treatment for chronic insomnia in adults of any age (including patients with comorbidities), either applied in‐person or digitally (A). When cognitive‐behavioural therapy for insomnia is not sufficiently effective, a pharmacological intervention can be offered (A). Benzodiazepines (A), benzodiazepine receptor agonists (A), daridorexant (A) and low‐dose sedating antidepressants (B) can be used for the short‐term treatment of insomnia (≤ 4 weeks). Longer‐term treatment with these substances may be initiated in some cases, considering advantages and disadvantages (B). Orexin receptor antagonists can be used for periods of up to 3 months or longer in some cases (A). Prolonged‐release melatonin can be used for up to 3 months in patients ≥ 55 years (B). Antihistaminergic drugs, antipsychotics, fast‐release melatonin, ramelteon and phytotherapeutics are not recommended for insomnia treatment (A). Light therapy and exercise interventions may be useful as adjunct therapies to cognitive‐behavioural therapy for insomnia (B).

2 August 2021 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
LKLukas B. Krone
Lukas B. Krone
TYTomoko Yamagata
Tomoko Yamagata
CBCristina Blanco-Duque
Cristina Blanco-Duque
MGMathilde C. C. Guillaumin
Mathilde C. C. Guillaumin
MKMartin C. Kahn
Martin C. Kahn
VVVladyslav V. Vyazovskiy
Vladyslav V. Vyazovskiy

29 May 2024 in Journal of Sleep Research
Verified
Journal Article
Open access
DRDieter Riemanm
Dieter Riemanm
RDRaphael Jan Dressle
Raphael Jan Dressle
FBFee Benz
Fee Benz
KSKai Spiegelhalder
Kai Spiegelhalder
AJAnna F. Johann
Anna F. Johann
BFBernd Feige
Bernd Feige
Summary: The world‐wide prevalence of insomnia disorder reaches up to 10% of the adult population. Women are more often afflicted than men, and insomnia disorder is a risk factor for somatic and mental illness, especially depression and anxiety disorders. Persistent hyperarousals at the cognitive, emotional, cortical and/or physiological levels are central to most theories regarding the pathophysiology of insomnia. Of the defining features of insomnia disorder, the discrepancy between minor objective polysomnographic alterations of sleep continuity and substantive subjective impairment in insomnia disorder remains enigmatic. Microstructural alterations, especially in rapid eye movement sleep (“rapid eye movement sleep instability”), might explain this mismatch between subjective and objective findings. As rapid eye movement sleep represents the most highly aroused brain state during sleep, it might be particularly prone to fragmentation in individuals with persistent hyperarousal. In consequence, mentation during rapid eye movement sleep may be toned more as conscious‐like wake experience, reflecting pre‐sleep concerns. It is suggested that this instability of rapid eye movement sleep is involved in the mismatch between subjective and objective measures of sleep in insomnia disorder. Furthermore, as rapid eye movement sleep has been linked in previous works to emotional processing, rapid eye movement sleep instability could play a central role in the close association between insomnia and depressive and anxiety disorders.

18 May 2023 in Journal of Sleep Research
Verified
Journal Article
Open access
LKLukas B. Krone
Lukas B. Krone
KFKristoffer D. Fehér
Kristoffer D. Fehér
TRTania Rivero
Tania Rivero
XOXimena Omlin
Ximena Omlin
Summary: Despite the success of cognitive behavioural therapy for insomnia and recent advances in pharmacotherapy, many patients with insomnia do not sufficiently respond to available treatments. This systematic review aims to present the state of science regarding the use of brain stimulation approaches in treating insomnia. To this end, we searched MEDLINE, Embase and PsycINFO from inception to 24 March 2023. We evaluated studies that compared conditions of active stimulation with a control condition or group. Outcome measures included standardized insomnia questionnaires and/or polysomnography in adults with a clinical diagnosis of insomnia. Our search identified 17 controlled trials that met inclusion criteria, and assessed a total of 967 participants using repetitive transcranial magnetic stimulation, transcranial electric stimulation, transcutaneous auricular vagus nerve stimulation or forehead cooling. No trials using other techniques such as deep brain stimulation, vestibular stimulation or auditory stimulation met the inclusion criteria. While several studies report improvements of subjective and objective sleep parameters for different repetitive transcranial magnetic stimulation and transcranial electric stimulation protocols, important methodological limitations and risk of bias limit their interpretability. A forehead cooling study found no significant group differences in the primary endpoints, but better sleep initiation in the active condition. Two transcutaneous auricular vagus nerve stimulation trials found no superiority of active stimulation for most outcome measures. Although modulating sleep through brain stimulation appears feasible, gaps in the prevailing models of sleep physiology and insomnia pathophysiology remain to be filled. Optimized stimulation protocols and proof of superiority over reliable sham conditions are indispensable before brain stimulation becomes a viable treatment option for insomnia.

1 May 2019 in Brain Stimulation
Verified
Journal Article
Closed access
LFLukas Frase
Lukas Frase
PSPeter Selhausen
Peter Selhausen
LKLukas Krone
Lukas Krone
STSulamith Tsodor
Sulamith Tsodor
FJFriederike Jahn
Friederike Jahn
Christoph NissenChristoph Nissen
Christoph Nissen

9 March 2023 in eLife
Verified
Journal Article
Open access
JTJanine Traut
Janine Traut
JMJose Prius Mengual
Jose Prius Mengual
EMElise J Meijer
Elise J Meijer
LMLaura E McKillop
Laura E McKillop
HAHannah Alfonsa
Hannah Alfonsa
LKLukas B Krone
Lukas B Krone
Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research, potential effects of the DREADD actuator clozapine-N-oxide (CNO) on sleep have never been systematically tested. Here, we show that intraperitoneal injections of commonly used CNO doses (1, 5, and 10 mg/kg) alter sleep in wild-type male laboratory mice. Using electroencephalography (EEG) and electromyography (EMG) to analyse sleep, we found a dose-dependent suppression of rapid eye movement (REM) sleep, changes in EEG spectral power during non-REM (NREM) sleep, and altered sleep architecture in a pattern previously reported for clozapine. Effects of CNO on sleep could arise from back-metabolism to clozapine or binding to endogenous neurotransmitter receptors. Interestingly, we found that the novel DREADD actuator, compound 21 (C21, 3 mg/kg), similarly modulates sleep despite a lack of back-metabolism to clozapine. Our results demonstrate that both CNO and C21 can modulate sleep of mice not expressing DREADD receptors. This implies that back-metabolism to clozapine is not the sole mechanism underlying side effects of chemogenetic actuators. Therefore, any chemogenetic experiment should include a DREADD-free control group injected with the same CNO, C21, or newly developed actuator. We suggest that electrophysiological sleep assessment could serve as a sensitive tool to test the biological inertness of novel chemogenetic actuators.